Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Champions Oncology, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 32 | 1 | 29 | −2 |
| Shares | 6.24M | 62.5K | 6.00M | −171.7K (−2.8%) |
| Value | $46.8M | $469.0K | $27.1M | −$19.2M (−41.5%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Champions Oncology, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Steward Financial Group LLC | 775 | $3.00K | 0.00% |
Sold out (3)
Institutions that held Champions Oncology, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Ergoteles LLC | 13,937 | $105.0K |
| Barclays PLC | 1,342 | $10.0K |
| Simplex Trading, LLC | 94 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Champions Oncology, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ACT Capital Management, LLC | 62,500 | $469.0K |